Alton Pharma

Alton Pharma appears to have been a small pharmaceutical drug discovery company centered on small-molecule histone deacetylase inhibitor prodrugs. Publicly visible evidence is limited, and most identifiable activity comes from patent filings rather than a current operating website, financing history, or commercial product record. Its disclosed work focused on prodrugs of hydroxamic acid-based histone deacetylase inhibitors, including compounds related to suberoylanilide hydroxamic acid, with intended applications in oncology as well as inflammatory, autoimmune, and neurodegenerative diseases. Based on the available record, the company does not appear to be an active operating biopharma company today, and there is no clear evidence of a marketed product pipeline or public-company status.